2. Metabolic Enzyme/Protease Cell Cycle/DNA Damage Apoptosis
  3. Phosphodiesterase (PDE) DNA/RNA Synthesis Apoptosis Ferroptosis
  4. TDP1-IN-6

TDP1-IN-6 is a TDP1 inhibitor with an IC50 of 1.52 μM. Combination of TDP1-IN-6 with Topotecan (HY-13768) enhances DNA damage, induces Apoptosis, triggers S-phase cell cycle arrest, and promotes Ferroptosis. TDP1-IN-6 can be used for the research of cervical cancer.

For research use only. We do not sell to patients.

TDP1-IN-6

TDP1-IN-6 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

TDP1-IN-6 Related Antibodies

Top Publications Citing Use of Products

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms
PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TDP1-IN-6 is a TDP1 inhibitor with an IC50 of 1.52 μM. Combination of TDP1-IN-6 with Topotecan (HY-13768) enhances DNA damage, induces Apoptosis, triggers S-phase cell cycle arrest, and promotes Ferroptosis. TDP1-IN-6 can be used for the research of cervical cancer[1].

In Vitro

TDP1-IN-6 (Compound 16b) potently inhibits purified TDP1 enzyme by stably binding to the catalytic domain and DNA-binding domain of the protein, with an IC50 of 1.52 μM[1].
TDP1-IN-6 inhibits the viability of HeLa cervical cancer cells with an IC50 of 14.85 μM; it exerts synergistic cytotoxic effects when combined with Topotecan[1].
TDP1-IN-6 (used at 2-4 μM in combination with 2 μM TPT) enhances Topotecan-induced apoptosis of HeLa cervical cancer cells in a dose-dependent manner by regulating apoptosis-related proteins, including downregulating BCL-2, upregulating BAX, and activating caspases[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TDP1-IN-6 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: HeLa cervical cancer cells
Concentration: 2-4 μM TDP1-IN-6; 2 μM TPT
Incubation Time: 72 h (wound healing)
Result: Had no effect on colony formation, wound healing, or cell invasion when used alone.
Significantly reduced colony formation rates when combined with TPT: 0.50 for 2 μM TPT + 2 μM TDP1-IN-6; 0.33 for 2 μM TPT + 4 μM TDP1-IN-6.
Slowed wound healing when combined with TPT: 0.46 and 0.28 wound healing rates at 72 h for 2 μM TPT + 2 μM TDP1-IN-6 and 2 μM TPT + 4 μM TDP1-IN-6, respectively.
Reduced invasive cell counts by ~81.5% for 2 μM TPT + 4 μM TDP1-IN-6 compared to control when combined with TPT.
Parmacokinetics
Species Dose Route Bioavailability
Mice[1] 5 mg/kg i.p. 62.7 %
Mice[1] 10 mg/kg i.p. 71.6 %
In Vivo

TDP1-IN-6 (5-10 mg/kg; i.p.; every 2 days) alone does not exhibit significant antitumor activity in HeLa cervical cancer xenografts, but when combined with Topotecan, it exerts potent synergistic tumor growth inhibition with minimal additional toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (SPF grade)[1]
Dosage: 5 mg/kg (monotherapy; combination with TPT); 10 mg/kg (monotherapy; combination with TPT); 0.3 mg/kg (TPT, combination)
Administration: i.p.; every 2 days
Result: Did not significantly reduce tumor growth compared to control group (monotherapy at 5 mg/kg or 10 mg/kg).
Significantly inhibited tumor growth when combined with 0.3 mg/kg TPT, resulting in significantly lower tumor weights at study end point (5 mg/kg and 10 mg/kg).
Caused only slight decreases in mouse body weight (monotherapy).
Did not exacerbate body weight loss when coadministered with TPT.
Showed extensive necrotic areas and inflammatory cell infiltration in tumors from combination treatment groups.
Molecular Weight

522.60

Formula

C29H30N8O2
SMILES

CC1=NC(N)=CC(N2CCN(CC2)CCOC(C3=CC4=C(N5CCC6=C(C5=N4)NC7=CC=CC=C76)C=C3)=O)=N1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TDP1-IN-6 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TDP1-IN-6Phosphodiesterase (PDE)DNA/RNA SynthesisApoptosisFerroptosisDNA-binding domainsS-phase cell cycle arrestHeLa cervical cancer cellsTDP1ferroptosisapoptosiscervical cancercatalytic domainsDNA repairTyrosyl-DNA phosphodiesterase 1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TDP1-IN-6
Cat. No.:
HY-183546
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.